Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, ...

Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients ...

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...

Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...

Eli Lilly (NYSE: LLY) currently leads the weight loss market thanks to Zepbound. Given that analysts project this area will gain significant traction in the coming years, that may provide a strong ...

Adults with obesity receiving tirzepatide 10 mg or 15 mg may be able to maintain most of their weight loss after switching to ...

ATTAIN-Maintain found oral orforglipron preserved prior loss after injection-to-oral transition, with only 0.9 kg regain from ...

Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug ...

After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of ...